A phase I study combining Durvalumab (MEDI4736) with Tremelimumab demonstrated improved tumor responses in advanced NSCLC patients, compared to single agent therapy alone, regardless of PD-L1 status [19]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.